June, 2021 - Microbiome Times Magazine

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

June 7, 2021 Microbiome Times

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the completion of its target enrollment […]

Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD

June 4, 2021 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an […]

Global microbiome study discovers thousands of new species, maps urban antimicrobial resistance and reveals new drug candidates

June 3, 2021 Microbiome Times

About 12,000 bacteria and viruses collected in a sampling from public transit systems and hospitals around the world from 2015 to 2017 had never before been identified, according to a study by the International MetaSUB […]